


a second component comprising a compound of formula I



or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and

a third component comprising a pharmaceutically tolerated excipient;

wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about 0.3% to about 50% of the first component.

*claim 12*  
~~13. The composition as claimed in *claim 1*, wherein concentration of the second component is from about 0.5% to about 20% of the first component.~~

*claim 12*  
~~14. The composition as claimed in *claim 1*, wherein the concentration of the second component is from about 0.8% to about 15% of the first component.~~

*claim 12*  
~~15. The composition as claimed in *claim 1*, wherein the concentration of the second component is from about 1% to about 10% of the first component.~~

C  
3/  
16. The composition as claimed in claim 1, wherein the concentration of the second component is from about 1% to about 5% of the first component.

C  
4/  
17. The composition as claimed in claim 1, which comprises a first component and a second component in a form for rectal or oral administration.


18. The composition as claimed in claim 1, wherein the first component is separate from the second component, and the first and second components are of similar administration forms.

19. The composition as claimed in claim 1, wherein the first component is separate from the second component, and the first and second components are of different administration forms.

20. A method of treating an immunological disease comprising administering to a patient in need of such treatment, a therapeutically effective amount of a solid composition comprising

a first component comprising 5-methyl-4'-trifluoromethyl-4-isoxazolecarboxanilide;

a second component comprising a compound of formula I



or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and

a third component comprising a pharmaceutically tolerated excipient;

wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about 0.3% to about 50% of the first component.

<sup>7</sup><sub>21</sub>. The method of claim <sup>6</sup><sub>20</sub>, wherein the composition produces a hyperadditive increase in the immunosuppressive effect.

<sup>8</sup><sub>22</sub>. A method according to <sup>6</sup><sub>claim 20</sub>, wherein the immunological disease is an acute immunological disease.

<sup>9</sup><sub>23</sub>. A method according to <sup>8</sup><sub>claim 22</sub>, wherein the acute immunological disease is sepsis, allergy, graft-versus-host reaction, or host-versus-graft reactions.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

10  
24.

claim 20

A method according to claim 12, wherein the immunological disease is an autoimmune disease.

11  
25.

10  
claim 24

A method according to claim 15, wherein the autoimmune disease is rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis.


Atch 63

26. A method of treating a disease comprising administering to a patient in need of such treatment, a therapeutically effective amount of a solid composition

comprising

a first component comprising 5-methyl-4'-trifluoromethyl-4-isoxazolecarboxanilide;

a second component comprising a compound of formula I



or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and

a third component comprising a pharmaceutically tolerated excipient;


wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about 0.3% to about 50% of the

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

first component, and wherein the disease is atopic dermatitis, asthma, urticaria, rhinitis, uveitis, type II diabetes, cystic fibrosis, colitis, or hepatic fibrosis.

- B3  
Int  
AA
27. A method of treating a cancerous disease comprising administering to a therapeutically effective amount of a solid composition comprising
- a first component comprising 5-methyl-4'-trifluoromethyl-4-isoxazolecarboxanilide;
- a second component comprising a compound of formula I



or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and

- a third component comprising a pharmaceutically tolerated excipient;
- wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about 0.3% to about 50% of the first component.

- ~~28. A method according to claim 18, wherein the cancerous disease is lung cancer, leukemia, ovarian cancer, sarcoma, Kaposi's sarcoma, meningioma, intestinal~~